$ALNY
ALNYLAM PHARMACEUTICALS, INC.

2020 Q2 Form 10-Q Financial Statement

#000117867020000015 Filed on August 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $104.0M $44.71M
YoY Change 132.5% 49.51%
Cost Of Revenue $18.27M $4.326M
YoY Change 322.21%
Gross Profit $85.70M $40.39M
YoY Change 112.18%
Gross Profit Margin 82.43% 90.33%
Selling, General & Admin $127.9M $112.8M
YoY Change 13.41% 33.17%
% of Gross Profit 149.24% 279.21%
Research & Development $155.0M $163.9M
YoY Change -5.43% 19.12%
% of Gross Profit 180.87% 405.79%
Depreciation & Amortization $8.200M $9.800M
YoY Change -16.33% 345.45%
% of Gross Profit 9.57% 24.26%
Operating Expenses $282.9M $276.7M
YoY Change 2.25% 24.47%
Operating Profit -$198.9M -$236.3M
YoY Change -15.83% 22.83%
Interest Expense $27.25M $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $20.96M $17.75M
YoY Change 18.06% -38.52%
Pretax Income -$177.9M -$218.5M
YoY Change -18.59% 33.67%
Income Tax $1.326M $960.0K
% Of Pretax Income
Net Earnings -$179.2M -$219.5M
YoY Change -18.34% 34.19%
Net Earnings / Revenue -172.4% -490.86%
Basic Earnings Per Share -$1.56
Diluted Earnings Per Share -$1.56 -$2.021M
COMMON SHARES
Basic Shares Outstanding 114.9M shares
Diluted Shares Outstanding 114.9M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.839B $1.927B
YoY Change -4.55% 33.1%
Cash & Equivalents $580.8M $1.136B
Short-Term Investments $1.258B $790.5M
Other Short-Term Assets $88.30M $65.60M
YoY Change 34.6% 26.4%
Inventory $77.42M $40.59M
Prepaid Expenses
Receivables $69.12M $30.74M
Other Receivables $9.800M $0.00
Total Short-Term Assets $2.160B $2.064B
YoY Change 4.68% 37.35%
LONG-TERM ASSETS
Property, Plant & Equipment $439.1M $371.8M
YoY Change 18.12% 63.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $20.40M $9.687M
YoY Change 110.55% -31.62%
Total Long-Term Assets $1.214B $652.6M
YoY Change 86.0% 127.57%
TOTAL ASSETS
Total Short-Term Assets $2.160B $2.064B
Total Long-Term Assets $1.214B $652.6M
Total Assets $3.374B $2.716B
YoY Change 24.22% 51.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.13M $71.22M
YoY Change -63.32% 494.05%
Accrued Expenses $211.2M $138.8M
YoY Change 52.15% 54.45%
Deferred Revenue $107.6M $89.24M
YoY Change 20.56% 874.15%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $384.3M $328.6M
YoY Change 16.95% 189.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $30.00M
YoY Change -100.0% 0.0%
Other Long-Term Liabilities $18.86M $9.514M
YoY Change 98.18% 127.28%
Total Long-Term Liabilities $18.86M $9.514M
YoY Change 98.18% 127.28%
TOTAL LIABILITIES
Total Short-Term Liabilities $384.3M $328.6M
Total Long-Term Liabilities $18.86M $9.514M
Total Liabilities $1.975B $959.2M
YoY Change 105.86% 468.97%
SHAREHOLDERS EQUITY
Retained Earnings -$4.089B -$3.242B
YoY Change 26.1% 35.99%
Common Stock $5.521B $5.035B
YoY Change 9.65% 24.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.400B $1.757B
YoY Change
Total Liabilities & Shareholders Equity $3.374B $2.716B
YoY Change 24.22% 51.81%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$179.2M -$219.5M
YoY Change -18.34% 34.19%
Depreciation, Depletion And Amortization $8.200M $9.800M
YoY Change -16.33% 345.45%
Cash From Operating Activities -$135.3M $288.7M
YoY Change -146.87% -381.11%
INVESTING ACTIVITIES
Capital Expenditures -$16.70M -$21.30M
YoY Change -21.6% -6.17%
Acquisitions
YoY Change
Other Investing Activities -$424.6M -$268.2M
YoY Change 58.31% -414.05%
Cash From Investing Activities -$441.2M -$289.5M
YoY Change 52.4% -562.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 689.0M 412.6M
YoY Change 66.99% 7267.86%
NET CHANGE
Cash From Operating Activities -135.3M 288.7M
Cash From Investing Activities -441.2M -289.5M
Cash From Financing Activities 689.0M 412.6M
Net Change In Cash 112.5M 411.8M
YoY Change -72.68% -1293.62%
FREE CASH FLOW
Cash From Operating Activities -$135.3M $288.7M
Capital Expenditures -$16.70M -$21.30M
Free Cash Flow -$118.6M $310.0M
YoY Change -138.26% -487.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001178670
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36407
dei Entity Registrant Name
EntityRegistrantName
ALNYLAM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0602661
dei Entity Address Address Line1
EntityAddressAddressLine1
675 West Kendall Street,
dei Entity Address Address Line2
EntityAddressAddressLine2
Henri A. Termeer Square
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
551-8200
dei Local Phone Number
LocalPhoneNumber
551-8200
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ALNY
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
115969783 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
580829000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
547178000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1258425000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
975017000 USD
CY2020Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
86310000 USD
CY2019Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
13967000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
69115000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43011000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
77418000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
56348000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
88349000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80343000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
2160446000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1715864000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
439126000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
425179000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
229674000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
221197000 USD
CY2020Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
24725000 USD
CY2019Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
14825000 USD
CY2020Q2 alny Royalties Receivable Noncurrent
RoyaltiesReceivableNoncurrent
500000000 USD
CY2019Q4 alny Royalties Receivable Noncurrent
RoyaltiesReceivableNoncurrent
0 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
26125000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20396000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18069000 USD
CY2020Q2 us-gaap Assets
Assets
3374367000 USD
CY2019Q4 us-gaap Assets
Assets
2395134000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
49884000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
211186000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
197201000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33447000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
27688000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
107587000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
77821000 USD
CY2020Q2 alny Royalty Liability Current
RoyaltyLiabilityCurrent
5957000 USD
CY2019Q4 alny Royalty Liability Current
RoyaltyLiabilityCurrent
0 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
384302000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
352594000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
281618000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
276135000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
281530000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
318383000 USD
CY2020Q2 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
1008336000 USD
CY2019Q4 alny Royalty Liability Noncurrent
RoyaltyLiabilityNoncurrent
0 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18855000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9330000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
1974641000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
956442000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
115647000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
115647000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112188000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112188000 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1156000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1122000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5520320000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
5201176000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33212000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-36518000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4088538000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3727088000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1399726000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1438692000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3374367000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2395134000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
103962000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44714000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
203438000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78008000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19929000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4326000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33231000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7673000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
154996000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
163890000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
324567000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
293017000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
127896000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
112769000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
254657000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
202377000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
302821000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
280985000 USD
us-gaap Costs And Expenses
CostsAndExpenses
612455000 USD
us-gaap Costs And Expenses
CostsAndExpenses
503067000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-198859000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-236271000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-409017000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-425059000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
27248000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
27248000 USD
us-gaap Interest Expense
InterestExpense
0 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
3165000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8781000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
8645000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
16306000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45039000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-453000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
68071000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-410000 USD
CY2020Q2 alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
0 USD
CY2019Q2 alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
9422000 USD
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
0 USD
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
9422000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20956000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
17750000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49468000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25318000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-177903000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-218521000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-359549000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-399741000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1326000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
960000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1901000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1655000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-179229000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-219481000 USD
us-gaap Net Income Loss
NetIncomeLoss
-361450000 USD
us-gaap Net Income Loss
NetIncomeLoss
-401396000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.18
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.75
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
114911000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108576000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
113830000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
106997000 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-179229000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-219481000 USD
us-gaap Net Income Loss
NetIncomeLoss
-361450000 USD
us-gaap Net Income Loss
NetIncomeLoss
-401396000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1796000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
462000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2249000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
822000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
571000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
842000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
911000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
842000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-72000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
4282000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-146000 USD
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax
4282000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1153000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2978000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3306000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2618000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-180382000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-222459000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-358144000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-404014000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
1438692000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54221000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34578000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4459000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-182221000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
1349729000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91873000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
5301000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
99498000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33707000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1153000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-179229000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
1399726000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
1301965000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11409000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
-58000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
784000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381900000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32541000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
360000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-181915000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
1546986000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6182000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4022000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
1089000 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
390577000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30798000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2978000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-219481000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
1757195000 USD
us-gaap Profit Loss
ProfitLoss
-361450000 USD
us-gaap Profit Loss
ProfitLoss
-401396000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
15813000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
7694000 USD
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
18971000 USD
alny Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
18584000 USD
alny Interest Expense On Sale Of Future Royalties
InterestExpenseOnSaleOfFutureRoyalties
27248000 USD
alny Interest Expense On Sale Of Future Royalties
InterestExpenseOnSaleOfFutureRoyalties
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
68333000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
62635000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
69643000 USD
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
0 USD
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
0 USD
alny Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
9422000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
4372000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-1924000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
26099000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11934000 USD
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-1991000 USD
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
-18700000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
24178000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15040000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
13560000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5319000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2036000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
43559000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7090000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
399173000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
18235000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
15763000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-381491000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
100185000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36275000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65293000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1140421000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
834563000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
859354000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
713106000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
9900000 USD
us-gaap Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
300000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-327542000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-186750000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
151512000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21641000 USD
alny Proceeds From Sale Of Royalties Interest
ProceedsFromSaleOfRoyaltiesInterest
500000000 USD
alny Proceeds From Sale Of Royalties Interest
ProceedsFromSaleOfRoyaltiesInterest
0 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
99498000 USD
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
400000000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
381900000 USD
alny Payments For Transaction Costs Related To Sale Of Future Royalties And Debt
PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt
8128000 USD
alny Payments For Transaction Costs Related To Sale Of Future Royalties And Debt
PaymentsForTransactionCostsRelatedToSaleOfFutureRoyaltiesAndDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
742882000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
803541000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-196000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
33653000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
716973000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
549628000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
422631000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
583281000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1139604000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6402000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
25893000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15077000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1728000 USD
alny Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
500000000 USD
alny Liability Related To Sale Of Future Royalties
LiabilityRelatedToSaleOfFutureRoyalties
0 USD
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF BUSINESS<div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic alliances with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic partners. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and early commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In August 2018, we received approval for ONPATTRO from the United States Food and Drug Administration, or FDA, and began commercializing and generating product revenues in the U.S., and also received marketing authorization for ONPATTRO from the European Commission, or EC. As of June 30, 2020, we have launched ONPATTRO in the U.S., Europe, Japan and in several additional countries. In November 2019, we received approval for GIVLAARI from the FDA and began commercializing and generating product revenues in the U.S. in December 2019. In March 2020, we received marketing authorization for GIVLAARI from the EC, and as of June 30, 2020, we have launched GIVLAARI in several countries in Europe. Regulatory filings in additional markets are pending or planned for 2020 and beyond for both products.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In April 2020, we entered into a broad strategic financing collaboration with The Blackstone Group Inc. and certain of its affiliates which includes a purchase and sale agreement, a credit agreement, a stock purchase agreement, and potential funding for certain research and development activities, subject to completion of a definitive agreement, under which The Blackstone Group Inc., and certain of its affiliates, will provide up to $2.00 billion to support our advancement of innovative RNAi therapeutics. Each executed agreement is a separate unit of account and was recorded at fair value. Please read Note 5, Note 9 and Note 10, respectively, for additional information regarding each executed agreement set forth above.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Reclassification</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Certain prior period amounts in the condensed consolidated financial statements have been reclassified to conform to the current period presentation.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including sales, expenses, reserves and allowances, the supply of our products and product candidates, clinical trials and research and development costs, </span></div>will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
CY2020Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
9865000 USD
CY2019Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
14929000 USD
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
152258000 USD
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
153117000 USD
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
16826000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2019000 USD
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1091000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
31504000 USD
CY2020Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2019Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2020Q2 alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0 USD
CY2019Q2 alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0 USD
alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0 USD
alny Impairment Of Marketable Debt Securities
ImpairmentOfMarketableDebtSecurities
0 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1266038000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2512000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
126000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1268424000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1315012000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
246000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
109000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1315149000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
9999000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
340132000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1258425000 USD
CY2019Q4 alny Capitalized Inventory
CapitalizedInventory
0 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
975017000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1268424000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1315149000 USD
CY2020Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
43515000 USD
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
15418000 USD
CY2020Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
20686000 USD
CY2019Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
38275000 USD
CY2020Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
13217000 USD
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2655000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
77418000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
56348000 USD
CY2020Q2 alny Capitalized Inventory
CapitalizedInventory
11500000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
580829000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1136289000 USD
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
5000 USD
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
332000 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2447000 USD
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2983000 USD
CY2019Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
5600000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
583281000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1139604000 USD
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
3049000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-257000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3306000 USD
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-2962000 USD
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
-344000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2618000 USD
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5000000 shares
CY2019Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
77.50
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
381900000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33755000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30603000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68333000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62635000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13625000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14467000 shares

Files In Submission

Name View Source Status
0001178670-20-000015-index-headers.html Edgar Link pending
0001178670-20-000015-index.html Edgar Link pending
0001178670-20-000015.txt Edgar Link pending
0001178670-20-000015-xbrl.zip Edgar Link pending
alny-20200630.htm Edgar Link pending
alny-20200630.xsd Edgar Link pending
alny-20200630_cal.xml Edgar Link unprocessable
alny-20200630_def.xml Edgar Link unprocessable
alny-20200630_g1.jpg Edgar Link pending
alny-20200630_g2.jpg Edgar Link pending
alny-20200630_htm.xml Edgar Link completed
alny-20200630_lab.xml Edgar Link unprocessable
alny-20200630_pre.xml Edgar Link unprocessable
alny2020q210-qex311.htm Edgar Link pending
alny2020q210-qex312.htm Edgar Link pending
alny2020q210-qex321.htm Edgar Link pending
alny2020q210-qex322.htm Edgar Link pending
alny2020q2exhibit-101.htm Edgar Link pending
alny2020q2exhibit-102.htm Edgar Link pending
alny2020q2exhibit-103.htm Edgar Link pending
alny2020q2exhibit-105.htm Edgar Link pending
alny2020q2exhibit-106.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image111.jpg Edgar Link pending
image311.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending